Diclofenac Salts. V. Examples of Polymorphism among Diclofenac Salts with Alkyl-hydroxy Amines Studied by DSC and HSM
Abstract
:1. Introduction
2. Results and Discussion
2.1. Diclofenac salts
2.2. The molecule of diclofenac
2.3. FT-IR and Raman micro-spectroscopy
2.4. Thermal analysis
2.5. Tri-hydroxy cation
2.6. Di-hydroxy cation
2.7. Mono-hydroxy cation
2.7.1. Mono-alkyl
2.7.2. Di-alkyl
2.8. Solubility values
Aliphatic base | Acronym | B. p. (free base) (°C) | MW of the salt (anhydrous) | Tpeak of the salt melting (°C) | ΔHm (Kcal.mol-1) | ΔS m(cal.mol-1·K-1) | Solubility (mM) | |
---|---|---|---|---|---|---|---|---|
1 | Mono-ethanolamine | MEA | 169 | 357.23 | 101* | 2.6 | 7.0 | 26.5 |
2 | Di-ethanolamine | DEA | 269 | 401.29 | 130 | 6.8 | 16.8 | 45.0 |
3 | Tri-ethanolamine | TEA | 360 | 445.34 | 138 | 15.8 | 38.4 | 7.6 |
4 | Tris-methylol aminomethane | TRIS | 220 | 418.15 | 209 | 15.3 | 31.8 | 3.5 |
5 | Methyl-monoethanolamine | MeMEA | 156 | 372.15 | 78 | 1.1 | 3.1 | 25.4 |
6 | Dimethyl-monoethanolamine | diMeMEA | 135 | 385.29 | 111 | * | * | 54.4 |
7 | Ethyl-monoethanolamine | EtMEA | 170 | 385.29 | 97 | 2.7 | 7.3 | 33.8 |
8 | Diethyl-monoethanolamine | diEtMEA | 161 | 413.34 | 113 | 7.7 | 19.9 | 36.0 |
9 | Methyl-diethanolamine | MeDEA | 248 | 415.31 | 102 | 7.2 | 19.2 | 33.3 |
10 | Ethyl-diethanolamine | EtDEA | 246 | 430.15 | 76 | 6.6 | 18.9 | 25.2 |
3. Experimental Section
3.1. Materials
3.2. Methods
4. Conclusions
References and Notes
- Fini, A.; Fazio, G.; Rapaport, I. Diclofenac/N-(2-hydroxyethyl)pyrrolidine: a new salt for an old drug. Drug Exp. Clin. Res. 1993, 19, 81–88. [Google Scholar]
- Fini, A.; Fazio, G.; Fernández Hervás, M.J.; Holgado, M.A.; Rabasco, A.M. Factors governing the dissolution of diclofenac salts. J. Pharm. Sci. 1996, 4, 231–238. [Google Scholar]
- Ledwige, M.T.; Draper, S.M.; Wilcock, D.J.; Corrigan, O.I. Physicochemical characterisation of diclofenac N-(2-hydroxyethyl)pyrrolidine anhydrate and dehydrate crystalline forms. J. Pharm. Sci. 1996, 85, 16–21. [Google Scholar] [CrossRef]
- Fini, A.; Sanchez-Soto, P.J.; Fernandez-Hervas, M.J.; Holgado, M.A. Thermal analysis of the dehydrated form of a diclofenac salt. Int. J. Pharm. 1998, 165, 79–85. [Google Scholar] [CrossRef]
- Fini, A.; Fazio, G.; Rosetti, F.; Holgado, M.A.; Iruín, A.; Alvarez-Fuentes, J. Diclofenac salts. III. Alkaline and earth alkaline salts. J. Pharm. Sci. 2005, 94, 2416–2431. [Google Scholar] [CrossRef]
- Fini, A.; Fazio, G.; Gonzalez-Rodriguez, M.; Cavallari, C.; Passerini, N.; Rodriguez, L. Formation of ion-pairs in aqueous solutions of diclofenac salts. Int. J. Pharm. 1999, 187, 163–173. [Google Scholar] [CrossRef]
- Cheong, H.A.; Choi, H.K. Enhanced percutaneous absorption of piroxicam via salt formation with ethanolamines. Pharm. Res. 2002, 19, 1375–1380. [Google Scholar] [CrossRef]
- Minghetti, P.; Cilurzo, F.; Casiraghi, A.; Montanari, L.; Fini, A. Ex vivo study of transdermal permeation of four diclofenac salts from different vehicles. J. Pharm. Sci. 2007, 96, 814–823. [Google Scholar] [CrossRef]
- Fini, A.; Fazio, G.; Benetti, L.; Ghedini, V. Thermal analysis of some diclofenac salts with alkyl and alkylhydroxy amines. Thermochim. Acta 2007, 464, 65–74, Note: this article must be considered the 4th part of this series.. [Google Scholar] [CrossRef]
- Jones, P.H.; Rowley, E.K.; Weiss, A.L.; Bishop, D.L.; Chun, A.H.C. Insoluble erythromycin salts. J. Pharm. Sci. 1969, 58, 337–339. [Google Scholar] [CrossRef]
- O'Connor, K.M.; Corrigan, O.I. Preparation and characterization of a range of diclofenac salts. Int. J. Pharm. 2001, 226, 163–179. [Google Scholar] [CrossRef]
- O'Connor, K.M.; Corrigan, O.I. Comparison of the physicochemical characteristics of the N-(2-hydroethyl)pyrrolidine, diethylamine and sodium salt forms of diclofenac. Int. J. Pharm. 2001, 222, 281–293. [Google Scholar] [CrossRef]
- Ledwige, M.T.; Corrigan, O.I. Effects of surface active characteristics and solid state forms on the pH solubility profiles of drug solvent systems. Int. J. Pharm. 1998, 174, 187–200. [Google Scholar] [CrossRef]
- Castellari, C.; Sabatino, P. Anti-inflammatory drugs: 1-(2-hydroxyethyl)-pyrrolidinium salt of diclofenac. Acta Cryst. 1994, C50, 1723–1726. [Google Scholar]
- Fini, A.; Fazio, G.; Orienti, I.; Zecchi, V.; Rapaport, I. Chemical Properties-dissolution relationship. IV. Behaviour in solution of the diclofenac/N-(2-hydroxyethyl)pyrrolidine salt (DHEP). Pharm. Acta Helv. 1991, 66, 201–203. [Google Scholar]
- Castellari, C.; Ottani, S. Two monoclinic Forms of Diclofenac Acid. Acta Cryst. 1997, C53, 794–797. [Google Scholar]
- Jaiboon, N.; Yosin, K.; Ruangchaithaweesuk, S.; Chaichit, N.; Thutivoranath, R.; Siritaedmukul, K.; Hannongbua, S. New orthorhombic for of 2-[(2,6-dichlorophenyl)amino]benzeneacetic acid (Diclofenac acid). Anal Sci. 2001, 17, 1465–1466. [Google Scholar] [CrossRef]
- Castellari, C.; Ottani, S. Anti-Inflammatory Drugs. V. [Tris-(2-hydroxymethyl)methyl] ammonium 2-[(2,6-Dichlorophenyl)amino]phenylacetate (TRISH. D). Acta Cryst. 1997, C53, 482–486. [Google Scholar]
- Castellari, C.; Ottani, S. Diclofenac Salts. IV. Tris(2-hydroxyethyl)ammonium 2-(2,6-Dichloro phenylamino) phenylacetate. Acta Cryst. 1996, C52, 2619–2622. [Google Scholar]
- Fang, L.; Numajiri, S.; Kobayashi, D.; Ueda, H.; Nakayama, K.; Miyamae, H.; Morimoto, Y. Physicochemical and crystallographic characterization of mefenamic acid complexes with alkanolamines. J. Pharm Sci. 2004, 93, 144–154. [Google Scholar] [CrossRef]
- Castellari, C.; Ottani, S. Diclofenac Salts. II. Salt of 2-(2,6-dichlorophenylamino)phenylacetic acid with diethanolamine. Acta Cryst. 1995, C51, 2612–2615. [Google Scholar]
- Dhanaraj, V.; Vijayan, M. Crystal structures of 1:1 complexes of meclofenamic acid with choline and ethanolamine. Biochim. Biophys. Acta 1987, 924, 135–146. [Google Scholar] [CrossRef]
- Dhanaraj, V.; Vijayan, M. A hydrated 1:1 complex between niflumic acid and ethanolamine, C13H8F3N2O2-.C2H8NO+.H2O. Acta Cryst. 1983, C39, 1398–1401. [Google Scholar]
- Tantishaiyakul, V. Prediction of aqueous solubility of organic salts of diclofenac using PLS and molecular modelling. Int. J. Pharm. 2004, 275, 133–139. [Google Scholar] [CrossRef]
© 2010 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
Share and Cite
Fini, A.; Cavallari, C.; Ospitali, F. Diclofenac Salts. V. Examples of Polymorphism among Diclofenac Salts with Alkyl-hydroxy Amines Studied by DSC and HSM. Pharmaceutics 2010, 2, 136-158. https://doi.org/10.3390/pharmaceutics2020136
Fini A, Cavallari C, Ospitali F. Diclofenac Salts. V. Examples of Polymorphism among Diclofenac Salts with Alkyl-hydroxy Amines Studied by DSC and HSM. Pharmaceutics. 2010; 2(2):136-158. https://doi.org/10.3390/pharmaceutics2020136
Chicago/Turabian StyleFini, Adamo, Cristina Cavallari, and Francesca Ospitali. 2010. "Diclofenac Salts. V. Examples of Polymorphism among Diclofenac Salts with Alkyl-hydroxy Amines Studied by DSC and HSM" Pharmaceutics 2, no. 2: 136-158. https://doi.org/10.3390/pharmaceutics2020136
APA StyleFini, A., Cavallari, C., & Ospitali, F. (2010). Diclofenac Salts. V. Examples of Polymorphism among Diclofenac Salts with Alkyl-hydroxy Amines Studied by DSC and HSM. Pharmaceutics, 2(2), 136-158. https://doi.org/10.3390/pharmaceutics2020136